Highlights of ASCO 2023

被引：1
作者：
Neugut, Alfred, I [1 ,2 ,3 ,5 ]
Bates, Susan E. [1 ,2 ,4 ]
机构：
[1] Columbia Univ, Vagelos Coll Phys & Surg, Dept Med, New York, NY USA
[2] Columbia Univ, Vagelos Coll Phys & Surg, Herbert Irving Comprehens Canc Ctr, New York, NY USA
[3] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA
[4] James J Peters Bronx VA Med Ctr, Bronx, NY USA
[5] Columbia Univ Irving Med Ctr, Div Oncol, 722 West 168th St,Room 725, New York, NY 10032 USA
来源：
ONCOLOGIST | 2023年 / 28卷 / 09期
关键词：
CHEMOTHERAPY; STAGE; SURVIVAL; TRIAL;
D O I：
10.1093/oncolo/oyad222
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Considering presentations at this year's ASCO annual meeting, this editorial highlights a number of studies of interest, from adjuvant therapy studies to tumor agnostic therapy.
引用
收藏
页码：739 / 742
页数：4
相关论文
共 24 条
  • [1] Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes
    Burotto, Mauricio
    Wilkerson, Julia
    Stein, Wilfred D.
    Bates, Susan E.
    Fojo, Tito
    [J]. SEMINARS IN ONCOLOGY, 2019, 46 (01) : 83 - 99
  • [2] Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
    Connors, J. M.
    Jurczak, W.
    Straus, D. J.
    Ansell, S. M.
    Kim, W. S.
    Gallamini, A.
    Younes, A.
    Alekseev, S.
    Illes, A.
    Picardi, M.
    Lech-Maranda, E.
    Oki, Y.
    Feldman, T.
    Smolewski, P.
    Savage, K. J.
    Bartlett, N. L.
    Walewski, J.
    Chen, R.
    Ramchandren, R.
    Zinzani, P. L.
    Cunningham, D.
    Rosta, A.
    Josephson, N. C.
    Song, E.
    Sachs, J.
    Liu, R.
    Jolin, H. A.
    Huebner, D.
    Radford, J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (04) : 331 - 344
  • [3] Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study
    Conte, P.
    Frassoldati, A.
    Bisagni, G.
    Brandes, A. A.
    Donadio, M.
    Garrone, O.
    Piacentini, F.
    Cavanna, L.
    Giotta, F.
    Aieta, M.
    Gebbia, V.
    Molino, A.
    Musolino, A.
    Ferro, A.
    Maltoni, R.
    Danese, S.
    Zamagni, C.
    Rimanti, A.
    Cagossi, K.
    Russo, A.
    Pronzato, P.
    Giovanardi, F.
    Moretti, G.
    Lombardo, L.
    Schirone, A.
    Beano, A.
    Amaducci, L.
    Bajardi, E. A.
    Vicini, R.
    Balduzzi, S.
    D'Amico, R.
    Guarneri, V.
    Giarratano, Tommaso
    McMahon, Laura
    De Salvo, Gian Luca
    Dieci, Maria Vittoria
    Maiorana, Antonio
    Ficarra, Guido
    Caggia, Federica
    Grisolia, Deborah
    Bartolini, Stefania
    Lorusso, Vito
    Ardito, Raffaele
    Tartarone, Alfredo
    Vanella, Paola
    Taverniti, Cristiana
    Porpiglia, Mauro
    Spanu, Pier Giorgio
    Biglia, Nicoletta
    Andreis, Daniele
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (12) : 2328 - 2333
  • [4] Nine-weeks versus one-year trastuzumab for early-stage HER2+breast cancer: 10-year update of the Short-HER phase III randomized trial.
    Conte, Pier Franco
    Bisagni, Giancarlo
    Piacentini, Federico
    Sarti, Samanta
    Minichillo, Santino
    Anselmi, Elisa
    Aieta, Michele
    Gebbia, Vittorio
    Schirone, A.
    Musolino, Antonino
    Garrone, Ornelia
    Beano, A.
    Rimanti, Anita
    Giotta, Francesco
    Turletti, Anna
    Dieci, Maria Vittoria
    Vicini, Roberto
    Balduzzi, Sara
    D'Amico, R.
    Guarneri, Valentina
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA637 - LBA637
  • [5] Overall survival analysis from the ADAURA trial of adjuvant osimertinib in patients with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC).
    Herbst, Roy S.
    Tsuboi, Masahiro
    John, Tom
    Kato, Terufumi
    Majem, Margarita
    Grohe, Christian
    Wang, Jie
    Goldman, Jonathan W.
    Lu, Shun
    Su, Wu-Chou
    de Marinis, Filippo
    Shepherd, Frances A.
    Lee, Ki Hyeong
    Le, Nhieu
    Dechaphunkul, Arunee
    Kowalski, Dariusz M.
    Poole, Lynne
    Stachowiak, Marta
    Rukazenkov, Yuri
    Wu, Yi-Long
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL)
  • [6] Herrera AF, 2023, J CLIN ONCOL, V41
  • [7] Labori KJ, 2023, J CLIN ONCOL, V41
  • [8] Neoadjuvant chemotherapy versus surgery first for resectable pancreatic cancer (Norwegian Pancreatic Cancer Trial-1 (NorPACT-1)) - study protocol for a national multicentre randomized controlled trial
    Labori, Knut Jorgen
    Lassen, Kristoffer
    Hoem, Dag
    Gronbech, Jon Erik
    Soreide, Jon Arne
    Mortensen, Kim
    Smaaland, Rune
    Sorbye, Halfdan
    Verbeke, Caroline
    Dueland, Svein
    [J]. BMC SURGERY, 2017, 17
  • [9] INDIGO: A global, randomized, double-blinded, phase 3 study of vorasidenib versus placebo in patients with residual or recurrent grade 2 glioma with an IDH1/2 mutation.
    Mellinghoff, Ingo K.
    Van den Bent, Martin J.
    Blumenthal, Deborah T.
    Touat, Mehdi
    Peters, Katherine B.
    Clarke, Jennifer Leigh
    Mendez, Joe Sammy
    Welsh, Liam
    Mason, Warren P.
    Hottinger, Andreas Felix
    Sepulveda Sanchez, Juan Manuel
    Wick, Wolfgang
    Soffietti, Riccardo
    Schoenfeld, Steven
    Zhao, Dan
    Pandya, Shuchi Sumant
    Steelman, Lori
    Hassan, Islam
    Wen, Patrick Y.
    Cloughesy, Timothy Francis
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA1 - LBA1
  • [10] Vorasidenib in IDH1-or IDH2-Mutant Low-Grade Glioma
    Mellinghoff, Ingo K.
    van den Bent, Martin J.
    Blumenthal, Deborah T.
    Touat, Mehdi
    Peters, Katherine B.
    Clarke, Jennifer
    Mendez, Joe
    Yust-Katz, Shlomit
    Welsh, Liam
    Mason, Warren P.
    Ducray, Francois
    Umemura, Yoshie
    Nabors, Burt
    Holdhoff, Matthias
    Hottinger, Andreas F.
    Arakawa, Yoshiki
    Sepulveda, Juan M.
    Wick, Wolfgang
    Soffietti, Riccardo
    Perry, James R.
    Giglio, Pierre
    de la Fuente, Macarena
    Maher, Elizabeth A.
    Schoenfeld, Steven
    Zhao, Dan
    Pandya, Shuchi S.
    Steelman, Lori
    Hassan, Islam
    Wen, Patrick Y.
    Cloughesy, Timothy F.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (07) : 589 - 601
123